FIELD: immunology; medicine.
SUBSTANCE: invention relates to a method for treating the symptoms of an initial episode of a disease associated with vWF, in particular thrombocytopenic purpura (TTP), as well as the use of a kit containing a container with a polypeptide having two single immunoglobulin variable domains (ISVD), and instructions for use, where each ISVD directed against human vWF is presented under SEQ ID NO: 19 to treat the symptoms of an initial episode of TTP.
EFFECT: invention provides an effective treatment for an initial episode of TTP that is more severe and difficult to treat than a recurrent episode.
16 cl, 5 dwg, 10 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING TTP WITH IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND THEIR USE | 2015 |
|
RU2807602C2 |
| POLYPEPTIDES MODULATING SIGLEC-DEPENDENT IMMUNE RESPONSES | 2017 |
|
RU2776807C2 |
| TREATMENT METHODS FOR HEMOPHILIA A | 2019 |
|
RU2812863C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
| PREPARATION CONTAINING VIII FACTOR AND VON WILLEBRAND FACTOR PEPTIDES | 2015 |
|
RU2714154C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2014 |
|
RU2718850C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2014 |
|
RU2830289C2 |
| NUCLEIC ACID MOLECULES AND WAYS OF USING THEM | 2018 |
|
RU2819144C2 |
| RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THEIR THERAPEUTIC USE | 2018 |
|
RU2811435C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII | 2015 |
|
RU2721910C2 |
